Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …

Breast cancer, the most common type of cancer affecting women, encompasses a collection
of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical …

PURPOSE To update recommendations on appropriate use of breast cancer biomarker
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …

Background In the phase III IMpassion130 trial, combining atezolizumab with first-line
nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) …

The dense stroma of desmoplastic tumor limits nanotherapeutic penetration and hampers
the antitumor immune response. Here, we report a denaturation-and-penetration strategy …

Background Understanding the impact of the tumor immune microenvironment and
BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint …

Purpose The aim of the current study was to conduct a pooled analysis of studies that have
investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple …

Only a subgroup of triple-negative breast cancer (TNBC) responds to immune checkpoint
inhibitors (ICI). To better understand lack of response to ICI, we analyze 681 TNBCs for …

Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple …

Suppression of antitumor immune responses is one of the main mechanisms by which tumor
cells escape from destruction by the immune system. Myeloid-derived suppressor cells …